miv-cel CAR T-Cell: Kyverna’s 1-year benefit specs for SPS and MG

CGTlive® USA

Overview

Kyverna Therapeutics reported positive one-year data for mivocabtagene autoleucel (miv-cel), a CD19-directed CAR T-cell therapy, showing durable benefits in patients with Stiff Person Syndrome (SPS) and generalized myasthenia gravis (gMG). In SPS patients, the median improvement on the T25FW test reached 49% at month 12, with 95% sustaining a clinically meaningful response. Miv-cel was well-tolerated through one year of follow-up, with no high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) reported.

In Depth

Key Findings

Kyverna Therapeutics announced encouraging one-year clinical trial data for mivocabtagene autoleucel (miv-cel), a CD19-directed CAR T-cell therapy, demonstrating durable benefits in patients suffering from Stiff Person Syndrome (SPS) and generalized myasthenia gravis (gMG). This marks a significant validation for the long-term efficacy of CAR T-cell therapies in autoimmune diseases.

Technical & Clinical Details

Miv-cel works by genetically modifying a patient’s own T cells to express a chimeric antigen receptor (CAR) that recognizes the CD19 antigen on the surface of B cells, thereby specifically eliminating pathogenic B cells. For patients with Stiff Person Syndrome, the median improvement in the T25FW (25-foot walk time) test, a key primary endpoint, reached 49% at 12 months, with 95% of patients maintaining a clinically meaningful response. Persistent improvements were also observed in patients with generalized myasthenia gravis. The safety profile was robust, with no high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) reported during the one-year follow-up. This data introduces a new therapeutic paradigm for these challenging autoimmune conditions.

Background & Context

Both Stiff Person Syndrome and generalized myasthenia gravis are rare, severe autoimmune disorders affecting neuromuscular junctions and the central nervous system, respectively. Existing treatments primarily manage symptoms but rarely achieve a definitive cure. These diseases significantly impair patients’ quality of life, often leading to progressive physical disability. While CAR T-cell therapies have predominantly been used in hematological malignancies, their application to autoimmune diseases by targeting autoreactive B cells is gaining considerable attention. The CD19-directed approach is particularly promising given the widespread role of B cells in various autoimmune pathologies.

Strategic Significance & Outlook

The durable one-year efficacy and favorable safety data for miv-cel instill strong confidence in the future success of CAR T-cell therapy for these autoimmune diseases. Larger clinical trials are anticipated to further validate its long-term effectiveness and safety. If approved, miv-cel could become a transformative treatment option for patients with SPS and gMG, fundamentally altering the therapeutic landscape for these conditions. Moreover, this success is expected to catalyze the broader application of CAR T-cell therapies to other severe and refractory autoimmune disorders, expanding their clinical utility beyond oncology.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime